Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger, Karl J

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. [electronic resource] - Blood Apr 2005 - 3303-11 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0006-4971

10.1182/blood-2004-02-0749 doi


Animals
Antineoplastic Agents--pharmacology
Benzamides
Cell Survival--physiology
DNA-Binding Proteins--metabolism
Down-Regulation
Extracellular Signal-Regulated MAP Kinases--metabolism
Fusion Proteins, bcr-abl--genetics
Gene Expression Regulation, Leukemic--drug effects
Humans
Imatinib Mesylate
In Vitro Techniques
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
MAP Kinase Kinase Kinases--metabolism
Milk Proteins--metabolism
Myeloid Cell Leukemia Sequence 1 Protein
Neoplasm Proteins--genetics
Oligonucleotides, Antisense--pharmacology
Piperazines--pharmacology
Proto-Oncogene Proteins c-bcl-2--genetics
Pyrimidines--pharmacology
RNA, Small Interfering--pharmacology
STAT5 Transcription Factor
Trans-Activators--metabolism
Tumor Cells, Cultured
raf Kinases--metabolism
ras Proteins--metabolism